SBI Okasan Asset Management Co.Ltd. Acquires New Position in Boston Scientific Corporation $BSX

SBI Okasan Asset Management Co.Ltd. acquired a new stake in Boston Scientific Corporation (NYSE:BSX) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 19,236 shares of the medical equipment provider’s stock, valued at approximately $1,842,000.

Several other institutional investors and hedge funds have also made changes to their positions in the stock. Vanguard Group Inc. lifted its stake in Boston Scientific by 0.8% during the 3rd quarter. Vanguard Group Inc. now owns 138,249,447 shares of the medical equipment provider’s stock valued at $13,497,294,000 after acquiring an additional 1,115,337 shares during the period. Rathbones Group PLC lifted its stake in Boston Scientific by 20.9% during the 4th quarter. Rathbones Group PLC now owns 2,759,657 shares of the medical equipment provider’s stock valued at $263,133,000 after acquiring an additional 477,680 shares during the period. Tounjian Advisory Partners LLC acquired a new stake in Boston Scientific during the 4th quarter valued at approximately $1,477,000. Kepler Cheuvreux Suisse SA acquired a new stake in Boston Scientific during the 3rd quarter valued at approximately $26,955,000. Finally, Waycross Partners LLC acquired a new stake in Boston Scientific during the 4th quarter valued at approximately $2,384,000. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Boston Scientific

In other Boston Scientific news, Director Edward J. Ludwig bought 3,580 shares of the company’s stock in a transaction dated Wednesday, May 20th. The stock was acquired at an average price of $56.68 per share, with a total value of $202,914.40. Following the completion of the acquisition, the director directly owned 25,359 shares of the company’s stock, valued at $1,437,348.12. This represents a 16.44% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director David C. Habiger bought 2,250 shares of the company’s stock in a transaction dated Wednesday, May 20th. The shares were acquired at an average cost of $55.92 per share, with a total value of $125,820.00. Following the acquisition, the director directly owned 13,878 shares of the company’s stock, valued at approximately $776,057.76. This represents a 19.35% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders acquired 9,800 shares of company stock valued at $554,012 over the last 90 days. 0.34% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

Several brokerages have commented on BSX. TD Cowen decreased their price objective on shares of Boston Scientific from $115.00 to $100.00 and set a “buy” rating for the company in a research note on Monday, February 2nd. Robert W. Baird set a $70.00 price objective on shares of Boston Scientific in a research note on Thursday. Royal Bank Of Canada restated an “outperform” rating on shares of Boston Scientific in a research note on Thursday. Morgan Stanley cut their target price on shares of Boston Scientific from $130.00 to $118.00 and set an “overweight” rating for the company in a report on Thursday, February 5th. Finally, Stifel Nicolaus set a $75.00 target price on shares of Boston Scientific in a report on Wednesday. One equities research analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and five have issued a Hold rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $87.46.

Boston Scientific Price Performance

Shares of NYSE BSX opened at $49.12 on Friday. The firm has a market cap of $73.01 billion, a PE ratio of 20.55, a PEG ratio of 0.93 and a beta of 0.62. The firm has a fifty day moving average of $60.69 and a 200 day moving average of $78.84. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.22 and a current ratio of 1.90. Boston Scientific Corporation has a one year low of $48.41 and a one year high of $109.50.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 EPS for the quarter, topping the consensus estimate of $0.79 by $0.01. The company had revenue of $5.20 billion during the quarter, compared to analyst estimates of $5.19 billion. Boston Scientific had a net margin of 17.29% and a return on equity of 19.17%. The firm’s revenue was up 11.6% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.75 EPS. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. As a group, research analysts predict that Boston Scientific Corporation will post 3.37 EPS for the current fiscal year.

Boston Scientific announced that its Board of Directors has initiated a stock repurchase plan on Monday, May 18th that allows the company to buyback $5.00 billion in shares. This buyback authorization allows the medical equipment provider to buy up to 6.4% of its shares through open market purchases. Shares buyback plans are generally an indication that the company’s management believes its shares are undervalued.

Trending Headlines about Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Boston Scientific advanced several clinical programs, including updates on its FARAPULSE pulsed-field ablation study and a diabetic neuropathy trial that is nearing a key data milestone, which could support future product growth. Boston Scientific Advances FARAPULSE PFA Study in Atrial Fibrillation
• Positive Sentiment: Unusual options activity showed heavy call buying in BSX, suggesting some traders are positioning for a rebound.
• Neutral Sentiment: Wall Street brokerage consensus still leans bullish overall, with the stock holding a “Moderate Buy” rating from analysts.
• Neutral Sentiment: Boston Scientific continues to work on its device pipeline and capital deployment strategy, which may help offset current franchise weakness over time. Boston Scientific (BSX) Device Succeeds in Over 93% of Patients in Its Pivotal Trial
• Negative Sentiment: Wells Fargo downgraded Boston Scientific to Equal Weight from Overweight, citing uncertainty around the EP business and the WATCHMAN franchise. Wells Fargo cuts Boston Scientific to ’Equal Weight’ on Watchman slowdown
• Negative Sentiment: Management’s reduced 2026 organic growth outlook and comments about slower WATCHMAN procedures and competitive pressure in electrophysiology were the main catalysts behind the stock’s decline. Boston Scientific shares fall 10% on Watchman weakness, competitive pressures

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.